Home › Funds › Samsara BioCapital, LLC › SGP
Samsara BioCapital, LLC position in SGP
SPYGLASS PHARMA INC · Health Care
Samsara BioCapital, LLC reported holding 2,109,953 shares of SGP (SPYGLASS PHARMA INC) in its Q2 2026 13F filing — a position valued at US$47.0M, representing 3.86% of its reported portfolio and ranking #8 among its reported holdings. Samsara BioCapital, LLC has disclosed SGP holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's SGP position evolved
Samsara BioCapital, LLC first disclosed a stake in SGP in Q1 2026 at 2,109,953 shares (US$54.7M). Across 2 filings, Samsara BioCapital, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,109,953 shares valued at US$47.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.11M | $54.67M | New |
| Q2 2026 | 2.11M | $46.97M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SGP and 13F data
SGP (SPYGLASS PHARMA INC) is a Health Care company. 61 other funds we track also report a position in SGP — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$178.6M), NEA Management Company, LLC (US$164.6M), Sands Capital Alternatives, LLC (US$55.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SGP
- RA CAPITAL MANAGEMENT, L.P. 8.02M sh · $178.55M · Q2 2026
- NEA Management Company, LLC 7.39M sh · $164.55M · Q2 2026
- Sands Capital Alternatives, LLC 2.50M sh · $55.65M · Q2 2026
- Vestal Point Capital, LP 670.00K sh · $14.91M · Q2 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held SGP?
Samsara BioCapital, LLC has disclosed SGP holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Samsara BioCapital, LLC's current position in SGP?
As of Q2 2026, Samsara BioCapital, LLC holds 2.11M shares of SGP (SPYGLASS PHARMA INC), valued at $46.97M, representing 3.86% of its reported portfolio and ranking #8.
Has Samsara BioCapital, LLC been buying or selling SGP?
In the latest 13F filing (Q2 2026), Samsara BioCapital, LLC held unchanged its position in SGP.
Which other funds hold SGP?
Other major institutional holders of SGP include RA CAPITAL MANAGEMENT, L.P., NEA Management Company, LLC, Sands Capital Alternatives, LLC, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.